Latest Forum Topics /
Clearbridge
Last:0.001
-0.001
|
 Post Reply
|
|
Medical Stock - Strong Shareholders
|
|||||
|
wehuattogether88
Supreme |
19-Sep-2021 11:57
|
||||
|
x 0
x 0 Alert Admin |
This should be a better news for Clearbridge | ||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
18-Sep-2021 10:41
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge Announces Partial Early Redemption of Convertible Bonds Extension of the Maturity Date of the Remaining Convertible Bonds Reaffirms Confidence from Holders of the Convertible Bonds in the Group&rsquo s Healthcare Strategy in Asia
&bull Partial early redemption reduces interest payment obligations arising from the convertible bonds
&bull Extension of the maturity date of the remaining convertible bonds to 2024 provides financial flexibility to the Group for expansion of its business
&bull The Group&rsquo s balance sheet remained healthy with total assets increasing from S$96.99 million as at 31 December 2020 to S$100.47 million as at 30 June 2021, of which the Group&rsquo s cash at bank and short-term deposits stood at S$22.28 million
Asia&rsquo s integrated healthcare company, Clearbridge Health Limited (&ldquo Clearbridge&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ) (" 明 策 集 团 &rdquo ), is pleased to announce that Group will undertake a partial early redemption of S$3,525,000 in principal amount of convertible bonds on a pro rata basis (&ldquo Partial Early Redemption&rdquo ).
Following the completion of the Partial Early Redemption, the outstanding principal amount of the convertible bonds will be S$3,525,000.
Separately, Clearbridge and the holders of the convertible bonds have entered into an amendment deed to amend certain terms and conditions of the convertible bonds, the key of which was to extend the maturity date of the remaining convertible bonds for a further two years to 8 March 2024 and 17 May 2024, as the case may be, conditional upon completion of the Partial Early Redemption.
To pursue acquisitions and business opportunities in Asia&rsquo s healthcare industry, the Group had announced the issuance ofsuch convertible bonds amounting to S$11.0 million in January 2019. Since then, the outstanding principal amount of the convertible bonds has been progressively reduced with an aggregate of S$3.95 million in principal amount of the convertible bonds converted into ordinary shares of the Company in 2020.
Mr Jeremy Yee (余 斌 ), Executive Director and Chief Executive Officer of Clearbridge, said, &ldquo The early redemption of the convertible bonds is in line with our prudent capital management strategy, and it also reinforces our commitment to maintain a robust balance
sheet with enhanced financial flexibility.
More importantly, there is considerable potential in each of our business segments and the maturity extension reaffirms bondholders&rsquo confidence in our ambitious growth initiatives within Asia&rsquo s healthcare market.&rdquo
Since its listing on the SGX-ST in December 2017, the Group has quickly pivoted from a technology accelerator into an EBITDA-focused healthcare platform aligned with the emerging healthcare trends in Asia. The Group currently provides a broad base of healthcare solutions via 3 distinctive strategic business units (&ldquo SBUs&rdquo ) across Asia:
1. Medical centres and clinics
2. Healthcare systems and
3. Strategic medical technology investments.
With its EBITDA-focused business strategy, the Group has been adjusted EBITDA positive since the first half of 2020 and for the first half of 2021, the Group registered an adjusted EBITDA of S$0.41 million with revenue of S$16.22 million.
Under the Group&rsquo s medical centres and clinics business unit, there are medical clinics in Singapore and Hong Kong, a medical centre and clinic in the Philippines as well as a chain of 10 dental clinics in Singapore. In addition, the Group distributes medical, lifestyle and wellness products through in-house clinics, centres and third party channels.
For its healthcare systems business units, the Group currently manages a total of 46 hospital joint operation contracts in Indonesia serving close to 4 million patients per year with a Public- Private-Partnership Model, primarily in the area of renal care (through PT Tirta Medika Jaya (&ldquo TMJ&rdquo ) which was acquired in April 2018) and pathology (through PT Indo Genesis Medika (&ldquo IGM Labs&rdquo ) which was acquired in May 2019) at public and private hospitals (ranging from Class A hospitals to Class C hospitals) in Indonesia. The renal care services and laboratory testing services offered by TMJ and IGM Labs respectively are reimbursed through the Indonesia government&rsquo s health coverage program.
As part of its business strategy, the Group has been expanding its capabilities in medical distribution within the region. The Group has secured a purchase contract directly with the manufacturer to purchase the SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the " Sinopharm COVID-19 Vaccine" ) for use in Singapore and its subsidiary has been administering the Sinopharm COVID-19 vaccine since 30 August 2021.
With deep experience and familiarity working with health authorities, medical supply chain logistic partners and healthcare institutions, the Group also aims to procure and supply the Sinopharm COVID-19 vaccine in other countries within the region.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
TradeExpert
Veteran |
14-Sep-2021 18:46
|
||||
|
x 0
x 0 Alert Admin |
This counter been stagnant for awhile and seems dead. Unless... Some Bbs push it higher or have some impactful positive news....
|
||||
| Useful To Me Not Useful To Me | |||||
|
shk363
Elite |
13-Sep-2021 11:22
|
||||
|
x 0
x 0 Alert Admin |
the potential capital is huge
|
||||
| Useful To Me Not Useful To Me | |||||
|
albeniz
Veteran |
13-Sep-2021 11:14
|
||||
|
x 0
x 0 Alert Admin |
A pity that this counter does not provide dividends. Otherwise, I would have loaded up more. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
For_The_Next_Leg
Master |
13-Sep-2021 10:49
|
||||
|
x 0
x 0 Alert Admin |
$Clearbridge(1H3.SI) With the uptick in Singapore cases and possible more and more regulations around workplace, I believe more people will try to get vaccinated.
Company will probably stand to gain since its subsidiaries (Medic Surgical & Laser Clinic) is one of the company that is able to provide sinopharm vaccine.
https://www.businesstimes.com.sg/companies-markets/clearbridge-unit-to-purchase-sinopharm-covid-19-vaccine-for-use-in-singapore
|
||||
| Useful To Me Not Useful To Me | |||||
|
ozone2002
Supreme |
30-Aug-2021 19:00
|
||||
|
x 0
x 0 Alert Admin |
Last:0.125  +0.005inverse head and shoulders formed get ready for technically higher prices gd luck dyodd |
||||
| Useful To Me Not Useful To Me | |||||
|
shk363
Elite |
30-Aug-2021 11:42
|
||||
|
x 0
x 0 Alert Admin |
the growth n prospect is in Indonesia and maybe Philippines... | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
FlyingCat
Master |
30-Aug-2021 11:20
|
||||
|
x 0
x 0 Alert Admin |
Read properly i say in indonesia... 4mil customer per annual. say vaccination 8 mil alone for indonesia. 10 dollar gross profit. its 80 mil gross profit.. less watever expenses.. wats the amt... simple calculation.. i didnt say in sg.. i say in region With a Public-Private-Partnership Model, the Group currently manages a total of 43 hospital joint operation contracts across Indonesia serving close to 4 million patients per year. These contracts are primarily in the area of renal care (TMJ) and pathology (IGM Labs) at public and private hospitals (ranging from Class A hospitals to Class C hospitals) in Indonesia (Table 1).
|
||||
| Useful To Me Not Useful To Me | |||||
|
daytrader123
Member |
30-Aug-2021 11:02
|
||||
|
x 0
x 1 Alert Admin |
Clearbridge won' t have the capability to set up clinic chain, which isn' t its core business and it doesn' t make any sense to set up clinics for purpose of covid vaccines look at IHh, it only offers sinopharm in 2 hospitals and 2 shenton clinic, which means IHH does not foresee a very big demand and also, they probably didn' t bring in a huge quantity Take note that there is a gap of around 30 mins for each appointment for the covid vaccines. You can roughly estimate the volumne per clinic
|
||||
| Useful To Me Not Useful To Me | |||||
|
FlyingCat
Master |
30-Aug-2021 10:04
|
||||
|
x 0
x 0 Alert Admin |
i mean for clearbrige to grow | ||||
| Useful To Me Not Useful To Me | |||||
|
FlyingCat
Master |
30-Aug-2021 09:55
|
||||
|
x 0
x 0 Alert Admin |
Yes i tot for sinopharm to grow short term it need to grow the vaccination in other countries sg how to earn... but it jus show to the region clearbridge have the ' expertise' in doing the vaccination it does have a region of clinics in southeast asia particularly indonesia... yes cb don fit the bill of being the distributor in the region, not big enuff.. but maybe jeremy will jio china man to come invest into it n be partners... long shot hahahaha
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Joelton
Supreme |
30-Aug-2021 09:22
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge Health receives first shipment of Sinopharm Covid-19 Vaccine
Clearbridge Health has received its first batch of the Sinopharm Covid-19 Vaccine here in Singapore.
On Aug 9, the company announced it would be buying the vaccine directly from its manufacturers in China for use in Singapore.
The Sinopharm COVID-19 Vaccine has been authorised for conditional or emergency use in several countries including China, UAE, Malaysia, Thailand and Indonesia.
It has also been listed by the WHO for emergency use.
Medic Surgical & Laser Clinic, operated by a Clearbridge Health subsidiary, has been granted approval under the Health Sciences Authority of Singapore' s Special Access Route scheme to import and supply the Sinopharm COVID-19 Vaccine in Singapore for six months from July 6.
People can book an appointment at healthcare firm Clearbridge Health' s Medic Surgical and Laser Clinic at Tanjong Pagar Plaza from Saturday, and it will begin administering the vaccine on Monday.
The vaccine is priced at $98 for two doses, including goods and services tax (GST).
|
||||
| Useful To Me Not Useful To Me | |||||
|
SgYuan
Supreme |
30-Aug-2021 09:19
|
||||
|
x 0
x 0 Alert Admin |
clearbridge 1h
w4 116 px hit 118 w5 130 px hit 126 |
||||
| Useful To Me Not Useful To Me | |||||
|
PhillipTan
Supreme |
30-Aug-2021 04:27
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge Health receives first shipment of Sinopharm Covid-19 VaccineClearbridge Health has received its first batch of the Sinopharm Covid-19 Vaccine here in Singapore.On Aug 9, the company announced it would be buying the vaccine directly from its manufacturers in China for use in Singapore. The Sinopharm COVID-19 Vaccine has been authorised for conditional or emergency use in several countries including China, UAE, Malaysia, Thailand and Indonesia. It has also been listed by the WHO for emergency use. Medic Surgical & Laser Clinic, operated by a Clearbridge Health subsidiary, has been granted approval under the Health Sciences Authority of Singapore' s Special Access Route scheme to import and supply the Sinopharm COVID-19 Vaccine in Singapore for six months from July 6. Clearbridge shares closed Aug 27 at 12 cents, down 1.64% for the day and down 20% year to date. |
||||
| Useful To Me Not Useful To Me | |||||
|
daytrader123
Member |
29-Aug-2021 20:54
|
||||
|
x 0
x 1 Alert Admin |
Having a strong record in medical industry also means he knows that in the long run, sinopahrm will want to license out sinopahrm vaccines to a pharma companies that is able to market sinopharm vaccines to the market and CB doesn' t fit the bill
|
||||
| Useful To Me Not Useful To Me | |||||
|
daytrader123
Member |
29-Aug-2021 20:51
|
||||
|
x 0
x 1 Alert Admin |
Sorry to be wet blanket clearbridge' s main business is laboratory tests and ain' t into distribution of pharmaceutical products and this it' s business network won' t really help if it intends to supply sinopharm via its own chain of medical clinics, sorry to say that it doesn' t have sufficient medical clinics in Singapore as well as in the region. Raffles medical group benefited from swabs business and this is because of its medical clinics network and capability.. Clearbridge is no where near.. At the moment, sinopharm is via special access route and thus no license by HSA is required. In the long run when covid vaccines becomes a ' non-pandemic' vaccines, HSA will require pharma companies that import it in to apply for license... sinopharm will want to license out sinopharm vaccines to a pharma companies that have the capability and proper commercial team to market sinopharm in Singapore and in the region. As someone has pointed out Jeremy has many years in the industry, and thus he will be fully aware that clear-bridge does not fulfill the criteria that sinopharm will be looking for as a business partner to distribute sinopharm in the region as many big pharma companies fit the role better. thus, in the long run, don' t count Sinopharm vaccines as going to contribute much to Clearbridge business..
|
||||
| Useful To Me Not Useful To Me | |||||
|
tedlim
Veteran |
29-Aug-2021 18:43
|
||||
|
x 0
x 0 Alert Admin |
I see that the CEO, Jeremy, has strong track record in medical industry...look at cordlife and he has brought in new investors, raising S$11 million, earlier this year to expand the group' s businses growth.. Give it a bit more time...share price is all time low...can keep a lookout.
|
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
29-Aug-2021 18:35
|
||||
|
x 0
x 0 Alert Admin |
Singapore is prob a stepping stone for Cleabridge to bring the Sinopharm vaccine to regional markets since they have the business network. For IHH, based on Mdm Ho' s facebook post, it is prob thru this route.... pls do your own DD
|
||||
| Useful To Me Not Useful To Me | |||||
|
daytrader123
Member |
29-Aug-2021 16:02
|
||||
|
x 0
x 1 Alert Admin |
On 9th august, they announced about their purchase contract with sinopharm. It' s just a purchase contract, not a big deal but they also announced... it' s probably a small quantity, if it has been a huge quantity, they would have mentioned the quantity. Anyway it' s for 1 clinic use, quantity will not be huge. I am sure IHH also has a purchase contract with Sinopharm but you don' t see IHH making such annoucement...
|
||||
| Useful To Me Not Useful To Me | |||||